Nirvana Life Sciences Inc.
NIRV
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 77.84% | -115.50% | -24.16% | -9.29% | 84.04% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.90% | 155.78% | -198.03% | 20,400.00% | -100.07% |
| Change in Net Operating Assets | -838.78% | 38.38% | 1,823.53% | -91.54% | -64.04% |
| Cash from Operations | -3,762.22% | -81.82% | 52.86% | -2,525.00% | 81.40% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -92.88% | 263.64% | -214.10% | 609.43% | 15.22% |
| Total Debt Repaid | -- | 200.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 532.51% | 221.19% | -428.26% | 626.32% | 11.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -188.60% | 1,150.55% | -313.64% | -- |
| Net Change in Cash | -109.86% | 244.90% | -96.00% | -412.50% | 188.89% |